Rights & Society
EMA Recommends New Lung Cancer Treatment
The European Medicines Agency (EMA) has recommended granting marketing authorization for Imdylltra (tarlatamab) in the European Union. This new monotherapy is intended for adults suffering from relapsed extensive-stage small cell lung cancer. The recommendation is a step forward in providing additional treatment options for patients with this specific type of cancer. The next step involves the European Commission's formal approval for marketing authorization.
New treatment option recommended by EMA for certain lung cancer patients in the EU.